How are life sciences companies responding to immense change? Explore how pharmaceutical, biotech, medical devices and medtech companies plan to pursue growth whilst remaining risk-responsive. These reports are based on a survey conducted by Baker McKenzie in collaboration with Informa Pharma Intelligence, featuring insights from over 250 life sciences executives in the Americas, Europe and Asia Pacific.

 

Life Sciences Business Evolution Series

Report 1: How Digital Transformation and Data Are Shaping Business Models

As digital transformation reshapes business models with different emphases across regions, digitally enabled strategies are helping companies transition from product-only offerings to product-service hybrids, orient to patient mapping, pre-diagnostics solutions and enhancing treatment administration. These intertwined value chains are increasingly shaping the life sciences industry of the future.


 


               

Life Sciences Business Evolution Series

 

Report 2: Funding Growth and the Future of Life Sciences

Life sciences companies intend to leverage new and existing sources of growth including through M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements as well as avenues tied to corporate PPAs and green financing. Find out about these trajectories as well as continued VC investment and increasing appetite from private equity sponsors in pre-revenue stages.

Watch this two-minute video highlighting key takeaways from the report.


 


               

Shaping Growth - Supply Chains, Manufacturing and Collaboration

 

Report 3: Shaping Growth - Supply Chains, Manufacturing and Collaboration

Understanding supply chain and manufacturing trajectories; the landscape for therapies, modalities and indications; and how companies can grow through collaboration will be paramount for grasping the opportunities that come with the evolution of this industry. Find out how pharmaceutical, biotechnology, medical device and medtech companies will continue to leverage new and existing sources of growth over the next decade

Watch this two-minute video highlighting key takeaways from the report.

Henrique Frizzo, partner at Trench Rossi Watanabe (São Paulo),* participated in this report.

*Trench Rossi Watanabe and Baker McKenzie have executed a strategic cooperation agreement for consulting on foreign law.

 

Vivian Wu, Partner, FenXun Law* (Beijing) also contributed to this report.

*FenXun established a joint operation office with Baker McKenzie in China as Baker McKenzie FenXun, which was approved by the Shanghai Justice Bureau in 2015.